- 1. General Conditions
- 2. Additional Grant Conditions and Grantee Obligations
- 3. Ethical considerations
1. General Conditions
1.1 Application Forms
The Application Form may be obtained by clicking on the following link: Application Form.
Applications forms must be completed and submitted electronically to the Canadian Hemophilia Society (email@example.com) and one (1) original paper copy, including signatures, must be sent to the National Office of the Canadian Hemophilia Society:
666 Sherbrooke Street West, Suite 301, Montreal, QC H3A 1E7
1.2 Application Deadline
Completed application forms and supporting documents must arrive at the National Office of the Canadian Hemophilia Society by November 15, 2016. If the CHS receives the application after the deadline date but it is postmarked on or before the deadline date, then it is considered to have been submitted on time. The names of the successful applicants will be announced by March, 2017.
First time applicants are encouraged to seek advice from experienced investigators in the preparation of their applications.
Please note that the Research Proposal (Item 17 of the application) must not exceed 5000 words, excluding figures and references.
Supporting materials should include only previously published articles or materials accepted for publication.
1.3 Grant Year and Amount
Individual grants valued at $75,000 per year and per project will be awarded to researchers for a maximum of $150,000 which can be expended over 2 or 3 years. If a two year award is provided, the second year of funding is dependent on evidence of progress as described in the required progress report. Grant funding will begin on April 1 of each year.
1.4 Grant Payments
Yearly grants will normally be disbursed in two payments in each year and sent to the financial officer of the host institution.
1.5 Research Summaries
The Canadian Hemophilia Society (CHS) requires, within the application form, a 200-word typewritten lay description of the research to be undertaken (in non-scientific, Grade 12 readability) for inclusion in the Society's publications should the proposal be accepted.
1.6 Notification of Grants
Following funding decisions, successful applicants will be sent official notification informing them of the type, duration and amount of their grant. A copy of the notification is sent to the accountant at the institution concerned. The award must be acknowledged by returning an acceptance note within 15 days of the CHS notification otherwise the award will be withdrawn. Unsuccessful applicants are also advised at the conclusion of the project application review process.
The Research Peer Review Committee of the Canadian Hemophilia Society will make recommendations on the awarding of the grants and the final decision will be made by the CHS Board of Directors. No appeals will be considered.
2. Additional Grant Conditions and Grantee Obligations
2.1 Statement of Expenditures
A statement of all expenditures for the grant, signed by the candidate and the financial officer of each institution, must be received at the CHS's offices within 2 months of the end date of the grant term. An institution finance/expenditure report is acceptable to avoid duplication of effort by the researcher. Failure to fulfill this requirement may lead to exclusion from future research grant competitions. If delay is anticipated, the CHS must be informed.
2.2 Changes in the Use of the Grant
The use of funds for purposes other than stated in the application must be approved in advance by the CHS.
2.3 Unexpended Balances
The Canadian Hemophilia Society does not permit carrying forward into the next grant year an unexpected balance in excess of $5,000. Prior written request to the CHS is required to carry forward a balance that exceeds $5,000.
2.4 Termination of the Grant
Upon termination of the project, any unexpended balance of funds must be returned to the CHS.
2.5 Travel Expenses
A grantee may use $1,500 annually from the award for the purpose of travel in connection with the grant and, if needed, an additional amount representing one percent (1%) of the annual value of the award.
2.6 Title to Equipment
Title to any equipment obtained with the Canadian Hemophilia Society's funds shall be held by the host institution on the condition that for a 12 month period following termination of grant, the CHS may transfer title to another institution. Prior written authorization for the transfer of funds or equipment by a grantee to another institution must be obtained from the CHS.
2.7 Interim, Final Report & Abstract Requirements
Research grant recipients are required to provide a project progress report for each year of funding allocation. This report will serve as the basis for review of the project and approval of second year funding, where applicable. The progress report will also provide supporting rationale, if required, for approval of project modifications, and/or extension requests.
Within 2 months of the end of the funding period, the Canadian Hemophilia Society requires a final report on the results of the project. The CHS also requires that the researcher provide an approximately 250-word lay abstract (Grade 12 readability) describing the outcomes of the research for inclusion in the Society's publications and for presentation at the CHS medical and scientific symposiums.
Failure to fulfill these requirements can lead to exclusion from future research grant competitions. If delay is anticipated, the CHS must be informed.
2.8 Acknowledgement of Support
The Canadian Hemophilia Society MUST be informed of any publications that are based on research funded by the Canadian Hemophilia Society and all such publications MUST acknowledge the support of the Canadian Hemophilia Society and Pfizer Canada. Researchers are encouraged to present study results, when possible, even if preliminary, at hemophilia conferences (e.g., World Federation of Hemophilia Congress, Rendez-Vous, etc.).
2.9 Proprietary Rights
The CHS must be informed of any commercial exploitation arising from the CHS-supported activity. However, the CHS does not claim proprietary rights to inventions resulting from research supported by its funds. The onus is on the grantee to seek patent protection in collaboration with the university or institute for inventions or developments arising from the CHS-supported research.
2.10 Indirect / Overhead Costs
Grant funds must contribute towards the direct costs of the research program or project for which the funds were awarded. The Institution provides for indirect or overhead costs, such as the costs associated with facilities and basic utilities, the purchase and repair of office equipment, administration fees, insurance for equipment and research vehicles, and basic communication devices such as telephones and fax machines. The funds must be used effectively and economically, and the expenses must be essential for the research supported by the grant.
Health Charities Coalition of Canada Position Statement on Indirect Costs of Research (May 14, 2007):
It is the policy of the Health Charities Coalition of Canada (HCCC) that health charities should not fund the indirect costs associated with the research they fund. All HCCC members have agreed not to fund indirect costs. While the HCCC recognizes that these may indeed be legitimate expenditures, we believe the funding of such costs is the responsibility of governments and not donors.
While the CHS is not a member of HCCC, it nonetheless supports the position that indirect costs associated with research it funds are the responsibility of governments and/or research institutions and not its donors.
3. Ethical considerations
3.1 Adherence to Research Guidelines
An application to the Canadian Hemophilia Society for research support constitutes a pledge on the part of the applicants and their research institutions to respect all the guidelines of the Canadian Hemophilia Society, the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans, December 2010 (TCPS2), the Canadian Institutes of Health Research (CIHR), Natural Sciences and Engineering Research Council of Canada, Social Sciences and Humanities Research Council of Canada and the Canadian Council on Animal Care. In the event that these guidelines are not adhered to, the CHS will withhold funding.
Completed forms required for research involving human subjects, gene therapy in humans, animals and biohazards must be received by the CHS as soon as possible; funding of successful applications for research will be withheld by the CHS until full Research Ethics Board approval is provided in writing to the CHS. CHS review of the applications, by its Peer Review Committee, can proceed prior to Research Ethics Board (REB) approval.
3.2 Research Involving Human Subjects
Each project in a research proposal involving human subjects and gene therapy in humans must submit the complete designated form, authorized by the local institutional Research Ethics Board in accordance with the TCPS2 document of the Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada,and Social Sciences and Humanities Research Council of Canada, Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans, December 2010. The Tri-Council Policy Statement is available from the following website: www.pre.ethics.gc.ca/pdf/eng/tcps2/TCPS_2_FINAL_Web.pdf
The responsibility for filing a Clinical Trial Application ( CTA) with Health Canada for a human drug clinical trial rests with the Principal Investigator. Guidance on whether a CTA is required is found at:
www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/clini/cta-eng.php See: Overview of the Clinical Trial Application Process and Institution/Investigator Initiated Clinical Trials.
In addition, all continuing grantees involved in human subjects must submit the complete designated form on an annual basis. Receipt of this form is required for continuation of payment by the CHS of any funds committed for the following year.
3.3 Research on Somatic Cell Gene Therapy in Humans
The Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans, December 2010 must be adhered to. Any research related to this area must be reviewed by the local institutional Research Ethics Board.
3.4 Care and Use of Experimental Animals
The CHS requires that all experiments involving animals be conducted in an ethical way. The facilities for, and the care and use of animals, in any investigation the CHS supports must be in strict accordance with the guidelines set out by the Canadian Council on Animal Care (CCAC) in its publication, Guide to the Care and Use of Experimental Animals (Vol. 1, 1980 and revised in 1993; Vol. 2, 1984), available from:
The Canadian Council on Animal Care
1000 - 151 Slater St.
Ottawa, Ontario Canada K1P 5H3
Each proposal involving animals must have one copy of the designated form, completed and authorized by a local institutional Animal Care Committee, confirming its ethical acceptability (the composition of the committee is set forth in the CCAC Guide). In addition, all continuing grantees involved in research using animals must submit one complete form on an annual basis. Receipt of this form is required for continuation of payment by the CHS of any funds committed for the following year.
3.5 Research Involving Biohazards
Investigators proposing to engage in research involving animal and human pathogens and animal cells are required to comply with the Canadian Institutes of Health Research and Health and Welfare Canada Biosafety Laboratory Guidelines, 3rd Edition – 2004. These guidelines were jointly prepared with the Office of Biosafety of the Laboratory Centre for Disease Control of Health Canada and are available from:
Office of Biosafety
Laboratory Centre for Disease Control
Health Protection Branch
Ottawa, Ontario Canada K1A 0L2
or at www.phac-aspc.gc.ca/publicat/lbg-ldmbl-04/index-eng.php
These Guidelines cover the following types of research:
a) research involving animal and human pathogens;
b) research involving animal cells in culture;
c) research involving recombinant DNA molecules which might be harmful to humans, animals or the environment.
Each proposal involving research proposals covering the areas noted above must have one completed form, authorized by a local institutional committee, confirming that the level of containment implemented by the investigator meets the Canadian Institutes of Health Research's requirements.
In addition, all continuing grantees participating in research involving biohazards must submit a completed form on an annual basis. Receipt of this form is required for continuation of payment by CHS of any funds committed for the following year.
Disposal of Hazardous and Radio Active Materials
3.6 Research Involving Hazardous Compounds
Researchers are responsible for ensuring that their research conforms with the provincial statutes regarding disposal of chemical wastes. Researchers are also responsible for ensuring that research assistants and laboratory personnel are aware of any hazards posed by materials required for the research, that these personnel are adequately trained in handling and containment of such compounds, and that protective procedures are enforced, in compliance with the Occupational Health and Safety regulations of the province in which work is carried out.
3.7 Research Involving Radioactive Materials
Applicants who will be carrying out research using radioactive materials must be aware of, and comply with, all Atomic Energy Control Board regulations, recommended procedures, and safety precautions governing the use of such materials in Canada. Further information may be obtained from:
Office of Public Information
Atomic Energy Control Board
P.O. Box 1046, Station 'B'
270 Albert Street
Ottawa, Ontario Canada K1P 5S9
Tel: 613-995-5894 Fax: 613-995-5086